Michael P. Dwyer

2.4k total citations
32 papers, 1.4k citations indexed

About

Michael P. Dwyer is a scholar working on Organic Chemistry, Oncology and Molecular Biology. According to data from OpenAlex, Michael P. Dwyer has authored 32 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Organic Chemistry, 15 papers in Oncology and 14 papers in Molecular Biology. Recurrent topics in Michael P. Dwyer's work include Chemokine receptors and signaling (7 papers), DNA Repair Mechanisms (5 papers) and Cancer-related Molecular Pathways (5 papers). Michael P. Dwyer is often cited by papers focused on Chemokine receptors and signaling (7 papers), DNA Repair Mechanisms (5 papers) and Cancer-related Molecular Pathways (5 papers). Michael P. Dwyer collaborates with scholars based in United States, United Kingdom and Israel. Michael P. Dwyer's co-authors include Timothy J. Guzi, Kamil Paruch, Wolfgang Seghezzi, David Parry, Derek Wiswell, Thierry Fischmann, Nicole R. Davis, Fergus Shanahan, Stephen F. Martin and Ronald J. Doll and has published in prestigious journals such as Journal of the American Chemical Society, Physical Review Letters and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Michael P. Dwyer

31 papers receiving 1.4k citations

Peers

Michael P. Dwyer
Ellen M. Dobrusin United States
Timothy J. Guzi United States
Lian‐Sheng Li United States
Kamil Paruch Czechia
Elena Ardini Italy
Patrick A. Plé United Kingdom
Dennis J. McNamara United States
Matthias Rabiller Germany
John C. Kath United States
Morwenna Muir United Kingdom
Ellen M. Dobrusin United States
Michael P. Dwyer
Citations per year, relative to Michael P. Dwyer Michael P. Dwyer (= 1×) peers Ellen M. Dobrusin

Countries citing papers authored by Michael P. Dwyer

Since Specialization
Citations

This map shows the geographic impact of Michael P. Dwyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael P. Dwyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael P. Dwyer more than expected).

Fields of papers citing papers by Michael P. Dwyer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael P. Dwyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael P. Dwyer. The network helps show where Michael P. Dwyer may publish in the future.

Co-authorship network of co-authors of Michael P. Dwyer

This figure shows the co-authorship network connecting the top 25 collaborators of Michael P. Dwyer. A scholar is included among the top collaborators of Michael P. Dwyer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael P. Dwyer. Michael P. Dwyer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Morriello, Gregori J., Michael P. Dwyer, Yili Chen, et al.. (2021). Discovery of novel N-1 substituted pyrazolopyrimidinones as potent, selective PDE2 inhibitors. Bioorganic & Medicinal Chemistry Letters. 44. 128082–128082. 1 indexed citations
2.
Clasby, Martin C., Michael P. Dwyer, Keith Eagen, et al.. (2020). Discovery of hydroxy pyrimidine Factor IXa inhibitors. Bioorganic & Medicinal Chemistry Letters. 30(15). 127279–127279. 1 indexed citations
3.
Stachel, Shawn J., Richard Berger, Daniel V. Paone, et al.. (2018). Structure-Guided Design and Procognitive Assessment of a Potent and Selective Phosphodiesterase 2A Inhibitor. ACS Medicinal Chemistry Letters. 9(8). 815–820. 13 indexed citations
4.
Dwyer, Michael P. & Younong Yu. (2014). CXCR2 Receptor Antagonists: A Medicinal Chemistry Perspective. Current Topics in Medicinal Chemistry. 14(13). 1590–1605. 19 indexed citations
5.
Dwyer, Michael P. & Younong Yu. (2014). CXCR2 modulators: a patent review (2009 – 2013). Expert Opinion on Therapeutic Patents. 24(5). 519–534. 16 indexed citations
6.
Labroli, Marc, Michael P. Dwyer, Ruichao Shen, et al.. (2014). The identification of novel 5′-amino gemcitabine analogs as potent RRM1 inhibitors. Bioorganic & Medicinal Chemistry. 22(7). 2303–2310. 10 indexed citations
7.
Guzi, Timothy J., Kamil Paruch, Michael P. Dwyer, et al.. (2011). Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening. Molecular Cancer Therapeutics. 10(4). 591–602. 135 indexed citations
8.
Parry, David, Timothy J. Guzi, Fergus Shanahan, et al.. (2010). Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor. Molecular Cancer Therapeutics. 9(8). 2344–2353. 434 indexed citations
9.
Dwyer, Michael P., Kamil Paruch, Marc Labroli, et al.. (2010). Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: A template-based approach—Part 1. Bioorganic & Medicinal Chemistry Letters. 21(1). 467–470. 55 indexed citations
10.
Labroli, Marc, Kamil Paruch, Michael P. Dwyer, et al.. (2010). Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: A template-based approach—Part 2. Bioorganic & Medicinal Chemistry Letters. 21(1). 471–474. 62 indexed citations
11.
Dwyer, Michael P., et al.. (2010). Discovery of 3,4-Diaminocyclobut-3-ene-1,2-dione-Based CXCR2 Receptor Antagonists for the Treatment of Inflammatory Disorders. Current Topics in Medicinal Chemistry. 10(13). 1339–1350. 7 indexed citations
12.
Taveras, Arthur G., Michael P. Dwyer, Younong Yu, et al.. (2009). Fluoroalkyl α side chain containing 3,4-diamino-cyclobutenediones as potent and orally bioavailable CXCR2–CXCR1 dual antagonists. Bioorganic & Medicinal Chemistry Letters. 19(5). 1431–1433. 13 indexed citations
13.
Chao, Jianping, Michael P. Dwyer, Younong Yu, et al.. (2009). Diaminocyclobutenediones as potent and orally bioavailable CXCR2 receptor antagonists: SAR in the phenolic amide region. Bioorganic & Medicinal Chemistry Letters. 19(15). 4446–4449. 8 indexed citations
14.
Fischmann, Thierry, Alan Hruza, José S. Duca, et al.. (2007). Structure‐guided discovery of cyclin‐dependent kinase inhibitors. Biopolymers. 89(5). 372–379. 46 indexed citations
15.
Dwyer, Michael P., Kamil Paruch, Carmen Álvarez, et al.. (2007). Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors. Bioorganic & Medicinal Chemistry Letters. 17(22). 6216–6219. 29 indexed citations
16.
Gonsiorek, Waldemar, Xuedong Fan, David Hesk, et al.. (2007). Pharmacological Characterization of Sch527123, a Potent Allosteric CXCR1/CXCR2 Antagonist. Journal of Pharmacology and Experimental Therapeutics. 322(2). 477–485. 101 indexed citations
17.
Chao, Jianhua, Arthur G. Taveras, Jianping Chao, et al.. (2007). C(4)-alkyl substituted furanyl cyclobutenediones as potent, orally bioavailable CXCR2 and CXCR1 receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 17(13). 3778–3783. 38 indexed citations
18.
Merritt, J. Robert, Laura L. Rokosz, Kingsley H. Nelson, et al.. (2006). Synthesis and structure–activity relationships of 3,4-diaminocyclobut-3-ene-1,2-dione CXCR2 antagonists. Bioorganic & Medicinal Chemistry Letters. 16(15). 4107–4110. 42 indexed citations
19.
Dwyer, Michael P. & Stephen F. Martin. (2003). Synthesis of Cyclopropane-Containing Leu-Enkephalin Analogs. Humana Press eBooks. 23. 407–416.
20.
Mordechaǐ, S., N. Auerbach, G. R. Burleson, et al.. (1988). Giant dipole resonances built on isobaric analog states in pion double charge exchange. Physical Review Letters. 60(5). 408–411. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ellen M. Dobrusin Breakdown of academic impact, for papers by Timothy J. Guzi Breakdown of academic impact, for papers by Lian‐Sheng Li Breakdown of academic impact, for papers by Kamil Paruch Breakdown of academic impact, for papers by Elena Ardini Breakdown of academic impact, for papers by Patrick A. Plé Breakdown of academic impact, for papers by Dennis J. McNamara Breakdown of academic impact, for papers by Matthias Rabiller Breakdown of academic impact, for papers by John C. Kath Breakdown of academic impact, for papers by Morwenna Muir
Rankless by CCL
2026